APGE vs AZN
APGE: Apogee Therapeutics is a clinical-stage biotechnology firm developing advanced biologic therapies for inflammatory and immunology diseases, currently pending acquisition by AbbVie. AZN: AstraZeneca is a global pharmaceutical leader driving innovation in oncology, rare diseases, and specialized biopharmaceuticals to address major unmet medical needs worldwide.
Side-by-side fundamentals
| Metric | APGE | AZN | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $134.65 | $161.91 | |
| Market cap as of 2026-08-11 | $10.2B | $184.5B | |
| P/E as of 2026-08-11 | n/a | 23.84 | |
| PEG as of 2026-08-11 | -1.41 | 2.64 | APGE lower |
| Net margin as of 2026-08-11 | n/a | +17.0% | |
| Gross margin as of 2026-08-11 | n/a | +81.3% | |
| Operating margin as of 2026-08-11 | n/a | +22.8% | |
| ROE as of 2026-08-11 | -32.6% | +21.7% | AZN higher |
| ROA as of 2026-08-11 | -31.3% | +9.1% | AZN higher |
| Debt / equity as of 2026-08-11 | 0.00 | 0.64 | APGE lower |
| Revenue growth (YoY) as of 2026-08-11 | n/a | +8.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.8% | |
| Dividend yield as of 2026-08-11 | n/a | +2.0% | |
| Beta as of 2026-08-11 | 0.21 | 1.36 | |
| 1-year return as of 2026-08-10 close | +280.5% | +10.1% | APGE higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.